SMTL ID : 6pgp.2 (1 other biounit)

Crystal structure of human KRAS G12C covalently bound to a quinazolinone inhibitor

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.50 Å

Oligo State

monomer

Ligands

1 x GDP: GUANOSINE-5'-DIPHOSPHATE(Non-covalent)

GDP.1: 20 residues within 4Å: Chain A: A.25, C.26, G.27, V.28, G.29, K.30, S.31, A.32, F.42, V.43, D.44, N.130, K.131, D.133, L.134, S.159, A.160, K.161 Ligands: CA.2, OHY.4 22 PLIP interactions: 22 interactions with chain A Hydrogen bonds: A:A.25, A:G.27, A:V.28, A:G.29, A:K.30, A:S.31, A:A.32, A:V.43, A:Y.46, A:N.130, A:K.131, A:K.131, A:A.160, A:K.161 Water bridges: A:S.31, A:S.31, A:Y.46, A:Y.46 Salt bridges: A:K.30, A:D.133 pi-Stacking: A:F.42, A:F.42

2 x CA: CALCIUM ION(Non-covalent)

CA.2: 2 residues within 4Å: Chain A: S.31 Ligands: GDP.1 5 PLIP interactions: 1 interactions with chain A, 4 Ligand-Water interactions Metal complexes: A:S.31, H2O.1, H2O.1, H2O.1, H2O.2 CA.3: 1 residues within 4Å: Chain A: E.77 2 PLIP interactions: 2 interactions with chain A Metal complexes: A:E.77, A:E.77

1 x OHY: 6-chloro-7-(2-fluoro-6-hydroxyphenyl)-4-(4-propanoylpiperazin-1-yl)-1-[2-(propan-2-yl)phenyl]quinazolin-2(1H)-one(Covalent)

OHY.4: 19 residues within 4Å: Chain A: V.23, G.24, C.26, K.30, P.48, T.72, A.73, G.74, Q.75, E.76, R.82, D.83, M.86, H.109, Y.110, Q.113, I.114, V.117 Ligands: GDP.1 15 PLIP interactions: 15 interactions with chain A Hydrophobic interactions: A:M.86, A:Y.110, A:Q.113, A:Q.113, A:V.117 Hydrogen bonds: A:K.30, A:E.76, A:R.82, A:R.82, A:Y.110 Water bridges: A:D.83, A:R.116 pi-Stacking: A:Y.110, A:Y.110 pi-Cation interactions: A:R.82

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Lanman, B.A. et al., Discovery of a Covalent Inhibitor of KRASG12C(AMG 510) for the Treatment of Solid Tumors. J.Med.Chem. (2020)

Release Date

2019-12-25

Peptides

GTPase KRas: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

GTPase KRas

Related Entries With Identical Sequence